Navigation Links
Polaris Group Doses First Patient in Phase 1 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 in Pediatric Patients with Emphasis on Leukemia, Lymphoma and Sarcoma
Date:2/29/2012

SAN DIEGO, Feb. 29, 2012 /PRNewswire/ -- Polaris Group (Polaris) today announced that it has dosed the first patient in a Phase 1 clinical trial evaluating its lead cancer therapeutic, pegylated arginine deiminase (ADI-PEG 20), in pediatric patients with emphasis on leukemia, lymphoma and sarcoma cancers. These three cancers represent approximately 50% of all cancers that occur in the pediatric population.

Patients with advanced cancers who have failed current therapy will be eligible to be treated with ADI-PEG 20. In addition, a tumor specimen from these potentially eligible patients must be deficient in expression of the enzyme argininosuccinate synthetase, the rate limiting step in formation of arginine. Patients will be enrolled into cohorts of increased doses of ADI-PEG 20, and will receive weekly intramuscular injections of ADI-PEG 20 until disease progression.  The primary endpoints of the study are safety and efficacy, and secondary endpoints will include finding the maximum tolerated dose of ADI-PEG 20 in a pediatric tumor population.

The rationale for the use of ADI-PEG 20 in these cancers was previously reported by Polaris collaborators, using both cell based assays and xenograft mouse models. In addition, they found a high percentage of these cancer tissue specimens require arginine. This Phase 1 clinical study is being conducted at MD Anderson Cancer Center, Houston, Texas.

"We are delighted to begin this first study of ADI-PEG 20 in pediatric patients," said John Bomalaski, M.D., Executive Vice President, Medical Affairs, of Polaris. "We believe ADI-PEG 20 is a promising cancer therapeutic for these cancers, and we plan to initiate Phase 2 studies in adults with these cancers. ADI-PEG 20 as monotherapy is already in a Phase 3 global trial for patients with hepatocellular carcinoma, and in Phase 2 trials for patients with small cell lung carcinoma and mesothelioma. In addition, a Phase 1 trial in prostate cancer
'/>"/>

SOURCE Polaris Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan
2. FDA Approves Special Protocol Assessment for Phase 3 Trial of Polaris Groups Cancer Therapeutic, ADI-PEG 20, in the Treatment of Hepatocellular Carcinoma
3. Polaris Group Appoints Robert E. Hoffman as Chief Financial Officer
4. Current Study Offers Window into Automation & Outsourcing Practices Within Top Pharmaceutical Market Research Groups
5. Winner Medical Group Inc. to Host First Quarter 2012 Earnings Conference Call on Thursday, February 9, 2012 at 08:00 p.m. EST
6. Concord Medical Services Holdings Limited Engages Solebury Communications Group LLC to Establish a Strategic Investor Relations Program
7. Unity Management Group Subsidiary Announces First Contracts of 2012 with Purdue Pharma L.P. and Novartis
8. Utilizing Marketing Innovations to Engage with Customer Groups that are Key to the Pharmaceutical Industry
9. MiMedx Group, Inc. Board Announces Support for Chairman Parker H. "Pete" Petit
10. The Zacks Analyst Blog Highlights: UnitedHealth Group, Aetna, WellPoint, CIGNA and Wright Medical Group
11. MiMedx Group, Inc. to Present at the Noble Capital Markets 8th Annual Equity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014  With a vision to ensure safety ... Global Pharmaceutical and Biotech manufacturer selects and implements ... solution to protect their animal health brand.  ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... aggregated by the Xyntek and Antares solution is ...
(Date:10/22/2014)...   BioNano Genomics , the genome mapping ... to purchase an Irys™ System . Among them ... (NCI), NIH Intramural Sequencing Center (NISC) and Genoscope (The ... comprehensive view of a genome was a major ... deliver the scalability or reliability to detect and ...
(Date:10/22/2014)... Calif., Oct. 21, 2014 Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis systems, today reported financial results for ... Second quarter overview: , Revenues of $53.9 ... , Diluted EPS of $0.24, up 33% over last ... Service revenues from Abaxis Veterinary Reference Laboratories (AVRL) of ...
Breaking Medicine Technology:Xyntek and Antares Serialization Solution Protects Pets Too! 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14
... CryoLife, Inc. (NYSE: CRY ), an implantable ... Cardiogenesis Corporation (OTCQB: CGCP), a leading developer of surgical ... angina resulting from diffuse coronary artery disease, today announced ... approved a definitive agreement under which CryoLife will acquire ...
... Pharmaceuticals, Inc., has been informed by the National Institute ... the National Institutes of Health that patient enrollment has ... nonalcoholic steatohepatitis (NASH), which will evaluate Intercept,s first-in-class farnesoid ... novel therapy for NASH. The FXR Ligand NASH Treatment ...
Cached Medicine Technology:CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 2CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 3CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 4CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 5CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 6CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 7CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 8CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 9CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 10CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 11CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 12CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 13CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 14CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 15CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 16CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 17CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 18Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals' Obeticholic Acid (INT-747) in NASH 2Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals' Obeticholic Acid (INT-747) in NASH 3
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a world ... face, it certainly can be difficult to choose the right ... favor by doing it the healthy way? Set aside the ... your body, exercise regularly, and choose foods with the most ... you need to exercise more and eat less. Despite the ...
(Date:10/22/2014)... 2014 Akeso Biomedical, Inc. , ... treatment of bacterial infections, microbial biofilms, and chronic wounds, ... board of directors. , Dr. Sinskey ... The Massachusetts Institute of Technology, or MIT. He has ... Dr. Sinskey also holds positions as Co-Director of the ...
(Date:10/22/2014)... Tara Haelle HealthDay ... Binge drinking among young adult men may lead to increased ... drinking didn,t cause a similar rise in blood pressure for ... In fact, when young adult women drank lightly or moderately, ... the study found. "This finding parallels studies in older ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... was diagnosed with Ebola while working for NBC News ... leave the special isolation unit at Nebraska Medical Center in Omaha, ... hospital said Tuesday. A blood test confirmed by the U.S. ... can head home to Providence, R.I., NBC News reported ...
(Date:10/20/2014)... The Advocator Group, LLC is ... Foundation for Suicide Prevention’s (AFSP) Out of the Darkness ... organization that hosts hundreds of community walks throughout the ... used to help understand and prevent suicide through not ... well. , The Advocator Group shares this passion ...
Breaking Medicine News(10 mins):Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3
... of vegetables in childhood lower risk// of stroke.This link ... a very interesting study published in the journal Heart. ... not just due to exposure to risk factors in ... an entire lifetime. Previous studies have suggested that diets ...
... with the help of anti fungal medication itraconazole can ... Manchester have broken new grounds in asthma treatment by ... bronchopulmonary aspergillosis, which is a form of asthma. , ... treated with steroids or drugs that have equally disastrous ...
... the use of strontium ranelate to be used for treating ... drug it is important to observe the changes in the ... Journal has said that the drug strontium ranelate have an ... effect can be used in advantage of the treatment procedure. ...
... researchers at Massachusetts General Hospital// and the Harvard School of ... may lower the risk of type II diabetes in men. ... produce enough insulin or the cells ignore the insulin. Insulin ... sugar. Type II diabetes typically occurs in individuals older than ...
... stomach infections caused by Helicobacter pylori might be ... pylori are common bacteria that reside in the ... infections. Previous research had connected the bacteria with ... ischemic heart disease. ,Researchers have tested patients ...
... common genetical variants that increase the risk for developing// ... condition in which kidneys of the body are unable ... waste balance that is part of the metabolism practice. ... that can lead to toxicity of the body. Chronic ...
Cached Medicine News:Health News:Association between childhood diet and stroke 2
Long-Sleeve Bolero for targeted compression in the upper arms, upper back and shoulder areas. Plush-shielded hook and eye front closure for comfort and convenient application....
Fully lined with cotton material for extra softness against patients skin. The 3 single adjustable soft Velcro® band provides,downward pressure preventing implants from moving upward or to the s...
Sub Pectoral Bra...
Bra With Cups...
Medicine Products: